Syndax (SNDX) Q3 2026 Earnings Call Transcript

Syndax reported Q3 2026 revenue of $83.3 million, up 82% year over year; Revuforj net revenue was $60.7 million, while Niktimvo net sales were $67.4 million and generated $22.6 million in collaboration revenue for Syndax. Management cited 20% sequential growth in Revuforj new-patient starts, $551.1 million in cash and investments, and approximately $400 million in 2026 R&D and SG&A guidance, excluding an estimated $50 million in noncash stock compensation. The company said the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint and development in that indication will stop.

Analysis

The key signal is not the headline growth rate but a potentially changing Revuforj revenue engine: transplant pauses defer sales, while post-transplant maintenance can extend treatment duration. That creates a lagged cohort effect, so near-term prescriptions and revenue may not move in lockstep; the company’s own 2027 inflection framing is plausible but depends on patients actually restarting and remaining on therapy. Treat the transplant and duration figures cautiously: they are company-reported real-world estimates from evolving cohorts, not established long-term persistence data.

The larger valuation swing remains front-line AML, not NUP98 guideline inclusion. Front-line success could expand the addressable population and strengthen prescriber lock-in; failure on efficacy, tolerability, or survival would leave the thesis more reliant on relapsed/refractory growth and maintenance. ASH data in Q4 are an imminent sentiment catalyst, but supportive single-arm or immature data are not equivalent to pivotal success. JNJ and Sumitomo are competitive watch items; their impact depends on comparative efficacy, safety, indication breadth, and timing, not simply entry into the class.

Niktimvo’s growth supports a second commercial leg, but do not capitalize its reported product sales as Syndax revenue: Syndax records collaboration profit share, and the quarter’s margin contribution included a one-time benefit. The failed IPF study narrows axatilimab’s opportunity in that indication; it does not by itself invalidate cGVHD programs. Management’s peak-sales and profitability claims remain conditional, and the CFO handoff adds modest execution risk. Net: improving fundamentals, but the market may be pricing a smooth transition from commercial growth to front-line optionality before pivotal evidence arrives.

Key Decisions for Investors

• SNDX: Favor a small, staged long on weakness rather than chasing the earnings reaction. Q4 ASH updates and 2027 post-transplant persistence are catalysts; keep sizing modest because pivotal front-line timing and valuation are not established here.
• Use ASH data as a thesis checkpoint: prioritize cohort size and follow-up, CR/MRD results, survival, and tolerability. Reduce exposure if updates fail to support the pivotal assumptions or if enrollment/timing guidance deteriorates.
• Track quarterly Revuforj starts, total prescriptions, and post-transplant restart rates separately. A sustained rise in starts without improving prescription duration/restarts would weaken the maintenance-tailwind thesis; delayed transplant cohorts could also keep near-term revenue choppy.
• Do not infer a direct trade in INCY from Niktimvo sales growth: verify the partnership’s economics and Incyte’s reported contribution before assigning earnings sensitivity. No JNJ pair trade is warranted without comparative clinical data.